Global Lupus Erythematosus Treatment Market
Global Lupus Erythematosus Treatment Market

Lupus Erythematosus Treatment Comprehensive Study by Route of Administration (Oral, Intravenous, Subcutaneous), Treatment (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Disease-Modifying Anti-Rheumatic Drugs, Monoclonal Antibodies, Anticoagulants, Biologics, Others), End Use (Hospital, Specialty Clinics)

Lupus Erythematosus Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 225 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Lupus Erythematosus Treatment Market Scope
In the past years, the prognosis for people with chronic lupus erythematosus has greatly increased. Faster diagnosis, renal dialysis and transplantation, and improved general care (such as blood pressure control and osteoporosis treatment) have also played a part. In Lupus Erythematosus patients, osteoporosis is a common concern. They have a high risk of bone loss and fractures due to disease activity, immobility, and, most importantly, the use of glucocorticoids. Age, gender, osteoporosis, low BMI, fall risk, low vitamin D levels, and lifestyle are all risk factors. SLE affects almost all of the body's organs and systems. Glucocorticoids, antimalarials, traditional synthetic immunosuppressive medications, and biologic treatments are among the treatment options for SLE.

The Lupus Erythematosus Treatment market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Lupus Erythematosus Treatment market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), ImmuPharma LLC (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Anthera Pharmaceuticals Inc. (United States), Bristol-Myers-Squibb Company (United States), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co. (United States), Lycera Corporation (United States) and Mylan N.V. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sanofi S.A. (France), Aurinia Pharmaceuticals Inc. (Canada), Sandoz International GmbH (Germany), Novartis AG (Switzerland), Bayer AG (Germany) and Bio-Rad Laboratories Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Lupus Erythematosus Treatment market by Type, Application and Region.

On the basis of geography, the market of Lupus Erythematosus Treatment has been segmented into .

Market Leaders and their expansionary development strategies
On 5th April, 2021 - Sorrento Enters into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics, this Acquisition will Add ACEA’s Systemic Lupus Erythematosus and The Ultra-Orphan Indication of Hairy Cell Leukemia Capabilities to Sorrento’s Therapeutics Portfolio. and On 15th March, 2021 - Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc., This Acquisition Would Add Strong, Mid-Stage Biologics to The Company, Including VIB7734, Which Was Set to Start A Phase 2 Trial for Systemic Lupus Erythematosus (SLE).
On 30th December, 2020 - GlaxoSmithKline Declared FDA Approval for BENLYSTA (belimumab), the First Chronic Disease Treatment for Adult Patients with Lupus Nephritis (LN) Who Are Undergoing Regular Therapy. The Approval Covers Both the Intravenous and Subcutaneous Formulations of The Treatment. and On 2nd February, 2021 - Progentec Launched Care Management Platform “aiSLE MGMT” Specifically Designed and Engineered for Lupus (SLE) Patients and Clinicians, The New Device is an all-encompassing disease monitoring tool that incorporates biomarkers and automated care delivery.
United States, Food and Drug Administration “Systemic Lupus Erythematosus - Developing Medical Products for Treatment” - Provision Refers to Approval, Inspection and Dosage Limitations of Lupus Erythematosus Drugs across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA.

Market Trend
  • Growing Healthcare Infrastructure Due to Pandemic
  • Emergence of Fast and Efficient Techniques

Market Drivers
  • Prevalence of SLE Cases Across the Globe
  • Rising Healthcare Awareness
  • Technical Progress Corticoid Applications

Opportunities
  • Low Penetration in Emerging Regions Particularly Asia

Restraints
  • Skewed Player Distribution

Challenges
  • Regulatory Approval
  • Lack of Trained Professionals


Key Target Audience
Lupus Erythematosus Drug Manufactures, New Entrants and Investors, Lupus Erythematosus Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently asked questions:
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Lupus Erythematosus Treatment Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous

By Treatment
  • Antimalarial Drugs
  • Non-Steroidal Anti-Inflammatory Drugs
  • Cytotoxic and Immunosuppressive Drugs
  • Disease-Modifying Anti-Rheumatic Drugs
  • Monoclonal Antibodies
  • Anticoagulants
  • Biologics
  • Others

By End Use
  • Hospital
  • Specialty Clinics

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Prevalence of SLE Cases Across the Globe
        • 3.2.2. Rising Healthcare Awareness
        • 3.2.3. Technical Progress Corticoid Applications
      • 3.3. Market Challenges
        • 3.3.1. Regulatory Approval
        • 3.3.2. Lack of Trained Professionals
      • 3.4. Market Trends
        • 3.4.1. Growing Healthcare Infrastructure Due to Pandemic
        • 3.4.2. Emergence of Fast and Efficient Techniques
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Lupus Erythematosus Treatment, by Route of Administration, Treatment and End Use (value) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Lupus Erythematosus Treatment (Value)
        • 5.2.1. Global Lupus Erythematosus Treatment by: Route of Administration (Value)
          • 5.2.1.1. Oral
          • 5.2.1.2. Intravenous
          • 5.2.1.3. Subcutaneous
        • 5.2.2. Global Lupus Erythematosus Treatment by: Treatment (Value)
          • 5.2.2.1. Antimalarial Drugs
          • 5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs
          • 5.2.2.3. Cytotoxic and Immunosuppressive Drugs
          • 5.2.2.4. Disease-Modifying Anti-Rheumatic Drugs
          • 5.2.2.5. Monoclonal Antibodies
          • 5.2.2.6. Anticoagulants
          • 5.2.2.7. Biologics
          • 5.2.2.8. Others
        • 5.2.3. Global Lupus Erythematosus Treatment by: End Use (Value)
          • 5.2.3.1. Hospital
          • 5.2.3.2. Specialty Clinics
    • 6. Lupus Erythematosus Treatment: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. GlaxoSmithKline plc (United Kingdom)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. ImmuPharma LLC (United Kingdom)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Anthera Pharmaceuticals Inc. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Bristol-Myers-Squibb Company (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Eli Lilly and Company (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Pfizer Inc. (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Merck & Co. (United States)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Lycera Corporation (United States)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Mylan N.V. (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global Lupus Erythematosus Treatment Sale, by Route of Administration, Treatment and End Use (value) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Lupus Erythematosus Treatment (Value)
        • 7.2.1. Global Lupus Erythematosus Treatment by: Route of Administration (Value)
          • 7.2.1.1. Oral
          • 7.2.1.2. Intravenous
          • 7.2.1.3. Subcutaneous
        • 7.2.2. Global Lupus Erythematosus Treatment by: Treatment (Value)
          • 7.2.2.1. Antimalarial Drugs
          • 7.2.2.2. Non-Steroidal Anti-Inflammatory Drugs
          • 7.2.2.3. Cytotoxic and Immunosuppressive Drugs
          • 7.2.2.4. Disease-Modifying Anti-Rheumatic Drugs
          • 7.2.2.5. Monoclonal Antibodies
          • 7.2.2.6. Anticoagulants
          • 7.2.2.7. Biologics
          • 7.2.2.8. Others
        • 7.2.3. Global Lupus Erythematosus Treatment by: End Use (Value)
          • 7.2.3.1. Hospital
          • 7.2.3.2. Specialty Clinics
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Lupus Erythematosus Treatment: by Route of Administration(USD Million)
    • Table 2. Lupus Erythematosus Treatment: by Treatment(USD Million)
    • Table 3. Lupus Erythematosus Treatment: by End Use(USD Million)
    • Table 4. Company Basic Information, Sales Area and Its Competitors
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Lupus Erythematosus Treatment: by Route of Administration(USD Million)
    • Table 15. Lupus Erythematosus Treatment: by Treatment(USD Million)
    • Table 16. Lupus Erythematosus Treatment: by End Use(USD Million)
    • Table 17. Research Programs/Design for This Report
    • Table 18. Key Data Information from Secondary Sources
    • Table 19. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Lupus Erythematosus Treatment: by Route of Administration USD Million (2015-2020)
    • Figure 5. Global Lupus Erythematosus Treatment: by Treatment USD Million (2015-2020)
    • Figure 6. Global Lupus Erythematosus Treatment: by End Use USD Million (2015-2020)
    • Figure 7. Global Lupus Erythematosus Treatment share by Players 2020 (%)
    • Figure 8. Global Lupus Erythematosus Treatment share by Players (Top 3) 2020(%)
    • Figure 9. Global Lupus Erythematosus Treatment share by Players (Top 5) 2020(%)
    • Figure 10. BCG Matrix for key Companies
    • Figure 11. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 12. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
    • Figure 13. ImmuPharma LLC (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 14. ImmuPharma LLC (United Kingdom) Revenue: by Geography 2020
    • Figure 15. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
    • Figure 16. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
    • Figure 17. Anthera Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 18. Anthera Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
    • Figure 19. Bristol-Myers-Squibb Company (United States) Revenue, Net Income and Gross profit
    • Figure 20. Bristol-Myers-Squibb Company (United States) Revenue: by Geography 2020
    • Figure 21. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
    • Figure 22. Eli Lilly and Company (United States) Revenue: by Geography 2020
    • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2020
    • Figure 25. Merck & Co. (United States) Revenue, Net Income and Gross profit
    • Figure 26. Merck & Co. (United States) Revenue: by Geography 2020
    • Figure 27. Lycera Corporation (United States) Revenue, Net Income and Gross profit
    • Figure 28. Lycera Corporation (United States) Revenue: by Geography 2020
    • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
    • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2020
    • Figure 31. Global Lupus Erythematosus Treatment: by Route of Administration USD Million (2021-2026)
    • Figure 32. Global Lupus Erythematosus Treatment: by Treatment USD Million (2021-2026)
    • Figure 33. Global Lupus Erythematosus Treatment: by End Use USD Million (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • GlaxoSmithKline plc (United Kingdom)
    • ImmuPharma LLC (United Kingdom)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Anthera Pharmaceuticals Inc. (United States)
    • Bristol-Myers-Squibb Company (United States)
    • Eli Lilly and Company (United States)
    • Pfizer Inc. (United States)
    • Merck & Co. (United States)
    • Lycera Corporation (United States)
    • Mylan N.V. (United States)
    Additional players considered in the study are as follows:
    Sanofi S.A. (France) , Aurinia Pharmaceuticals Inc. (Canada) , Sandoz International GmbH (Germany) , Novartis AG (Switzerland) , Bayer AG (Germany) , Bio-Rad Laboratories Inc. (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation